Form 4: Haemonetics EVP Llorens Reports Stock Transactions
SEC Form 4 Filing
Josep Llorens, EVP of Global Manufacturing at Haemonetics, reports the acquisition and disposal of company stock, including transactions under a 10b5-1 trading plan and vesting of restricted stock units.
Summary
- Josep Llorens, EVP of Global Manufacturing at Haemonetics Corp, filed a Form 4 detailing changes in beneficial ownership.
- On May 17, 2024, Llorens sold 822 shares of common stock at $94.82 per share under a 10b5-1 trading plan.
- Additionally on May 17, 2024, 320 shares were withheld for tax obligations related to vesting RSUs at $95.73.
- Also on May 17, 2024, Llorens acquired 6,267 shares in the form of RSUs, which vest 100% on the first anniversary of the grant date.
- On May 20, 2024, Llorens sold 987 shares of common stock at $95.08 per share under the 10b5-1 trading plan.
- Following these transactions, Llorens beneficially owns 21,310 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-existing plan and standard compensation practices. There is no indication of unusual activity or concern.
Positives
- The grant of 6,267 RSUs indicates continued alignment of executive compensation with company performance.
Future Outlook
The vesting of RSUs on the first anniversary of the grant date suggests continued employment and alignment with company goals.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Executive compensation packages often include RSUs to align management interests with shareholder value, a common practice among publicly traded companies like Haemonetics.
- The use of 10b5-1 trading plans is a standard method for insiders to sell shares without raising concerns about insider trading, similar to practices at companies like Medtronic or Boston Scientific.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding insider activity.
- The RSU grants incentivize management to improve company performance, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 2023-08-28 | Date of the 10b5-1 trading plan. |
| 2023-08-31 | 10b5-1 trading plan fully executed. |
| 2024-05-17 | Date of stock sale and RSU vesting. |
| 2024-05-20 | Date of stock sale. |
| 2024-05-21 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.